Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease

Abstract Alzheimer's disease (AD) is the most common form of dementia, and neuroinflammation is an important hallmark of the pathogenesis. Tumor necrosis factor (TNF) might be detrimental in AD, though the results coming from clinical trials on anti‐TNF inhibitors are inconclusive. TNFR1, one o...

詳細記述

書誌詳細

出版年:	EMBO Molecular Medicine
主要な著者:	Sophie Steeland, Nina Gorlé, Charysse Vandendriessche, Sriram Balusu, Marjana Brkic, Caroline Van Cauwenberghe, Griet Van Imschoot, Elien Van Wonterghem, Riet De Rycke, Anneke Kremer, Saskia Lippens, Edward Stopa, Conrad E Johanson, Claude Libert, Roosmarijn E Vandenbroucke
フォーマット:	論文
言語:	英語
出版事項:	Springer Nature 2018-02-01
主題:	Alzheimer's disease blood‐CSF barrier choroid plexus therapy TNF receptor 1
オンライン･アクセス:	https://doi.org/10.15252/emmm.201708300